Title: Alphaknife for glioma tumors: two years experiences with targeted alpha therapy of 213Bi-substance P
Citation: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41 no. Supplement 2 p. S 291 - Abstract n° OP603
Publisher: SPRINGER
Publication Year: 2014
JRC N°: JRC91273
ISSN: 1619-7070
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC91273
DOI: 10.1007/s00259-014-2901-9
Type: Articles in periodicals and books
Abstract: Glioblastoma multiforme (GBM) is characterized by the worst prognosis with an overall survival (OS) 9-15 months, median 13 months. The infiltrating character of the tumor, molecular heterogeneity, as well as the protective effects of blood-brain barrier are the causes of insufficient front line treatments (surgery, radio and chemotherapy); 90% of patients have a recurrence at the original tumor location. Therefore a new type of strategies must be implemented and proofed. It has been demonstrated that NK-1 receptor system is extensively expressed in glioma cells, and substance P can be used as a ligand for targeted therapy. On the other hand alpha emitter, like 213Bi offers the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.